If you have been reading about thymosin beta-4 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
The fission product mixture contains significant amounts of molybdenum. Molybdenum-99 is of enormous interest to nuclear medicine as the parent nuclide to 99mTc, but its short half-life means it will usually decay long before the spent fuel is reprocessed. 99Mo can be produced both by fission followed by immediate reprocessing (usually only done in small-scale research reactors) or in particle accelerators. As molybdenum-100 only decays extremely slowly via double beta decay (half-life longer than the age of the universe), the molybdenum content of spent fuel will be essentially stable after a few days have passed to allow the molybdenum-99 to decay.
== History == Lente insulin arose from research into ways to alter the pharmacokinetics of bovine or porcine insulin products. Prior to the late 1940s, insulin products were derived from pork or beef sources, and then used virtually unaltered as "short-acting" insulin products. It was known by 1950 that the addition of protamine or zinc could alter the duration of action of these insulin products, and in 1952, K. Hallas-Møller at Novo Nordisk produced the first commercial insulin zinc suspension for use in humans. For decades, lente insulin was used as a basal insulin, designed to mimic the body's continual slow release of insulin throughout the day. Compared to NPH insulin, lente insulin has a similar but more protracted loss of action after a dose is administered. In the 1990s, recombinant DNA technology allowed for the mass production of the human insulin protein in yeast or bacteria. This led to formulations of recombinant lente human insulin products by the early 2000s. However, lente insulin began to fall out of favor with doctors in the mid-2000s, when insulin analogues such as glargine began to be approved. Insulin analogues made by recombinant DNA production methods have less variation in their strength and purity between doses and batches. Furthermore, while lente insulin (and NPH) have a definitive peak in effect, insulin analogs have a much less pronounced peak, making for more predictable effects and less risk of hypoglycemia.
==== Textile finishing ==== Perfluorinated surfactants, such as fluorotelomer alcohols (FTOH), are used as coating agents for textiles, carpets, and construction products to impart or enhance water and grease repellency. As members of the PFC group, however, they are subject to criticism because they are persistent and practically non-degradable in nature.
==== Binary compounds ==== Potassium forms many binary compounds, i.e., compounds of potassium and one other element. The inventory is so extensive that one gap merits mention: no nitride of potassium is known. Potassium hydride forms directly from the elements:
Sources: en.wikipedia.org
=== In humans === Although generally considered safe to use, it is neurotoxic to humans in high doses. Pyrethroids like deltamethrin can also be an allergen that provokes asthma in some people. Deltamethrin temporarily attacks the nervous system of any animal with which it comes into contact. Skin contact can lead to tingling or reddening of the skin local to the application. If taken in through the eyes or mouth, the most common symptom is facial paraesthesia, which can feel like many different abnormal sensations, including burning, partial numbness, "pins and needles", skin crawling, etc. There is one case report describing chronic intoxication from pyrethroid insecticides leading to a syndrome clinically similar to motor neuron disease. There are no antidotes, and treatment must be symptomatic, as approved by a physician. Over time, deltamethrin is metabolized, with a rapid loss of toxicity, and passed from the body. A poison control center should be contacted in the event of an accidental poisoning. Deltamethrin is able to pass from a woman's skin through her blood and into her breast milk, although breastfeeding remains safe under prevailing conditions. In South Africa, residues of deltamethrin were found in breast milk, together with DDT, in an area that used DDT treatment for malaria control, as well as pyrethroids in small-scale agriculture. A 2015 study conducted in Brittany, France, found a negative correlation between deltamethrin exposure (measured through the presence of a metabolite in urine) and cognitive scores in infants.
Bucillamine is an antirheumatic agent developed from tiopronin. Activity is mediated by the two thiol groups that the molecule contains. Research done in USA showed positive transplant preservation properties. Bucillamine is currently being investigated for COVID-19 drug repurposing. Bucillamine has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. It is a cysteine derivative with 2 thiol groups that is 16-fold more potent than acetylcysteine (NAC) as a thiol donor in vivo, giving it vastly superior function in restoring glutathione and therefore greater potential to prevent acute lung injury during influenza infection. Bucillamine has also been shown to prevent oxidative and reperfusion injury in heart and liver tissues. Bucillamine has both proven safety and proven mechanism of action similar to that of NAC, but with much higher potency, mitigating the previous obstacles to using thiols therapeutically. It is hypothesized that similar processes related to reactive oxygen species (ROS) are involved in acute lung injury during nCov-19 infection, possibly justifying the investigation of bucillamine as an intervention for COVID-19. On July 31, 2020, the U.S. Food & Drug Administration (FDA) has approved Revive Therapeutics Ltd. to proceed with a randomized, double-blind, placebo-controlled confirmatory Phase 3 clinical trial protocol to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.
== Production and effects == Artificial production methods of radionuclides include neutron sources such as nuclear reactors, as well as particle accelerators such as cyclotrons. The radiation from radionuclides generally has a harmful effect on organisms including humans, although low levels of exposure occur naturally. The degree of harm depends on the nature and extent of the radiation (alpha, beta, gamma, or neutron), the amount and nature of exposure (close contact, inhalation or ingestion), and the element's biochemical properties (toxicity). Increased risk of cancer is unavoidable, and worse cases induce cancer, chronic radiation syndrome or acute radiation syndrome. Radionuclides can be used as weapons by the fallout effects of nuclear weapons and by radiological weapons. Radionuclides are used in nuclear medicine for both diagnosis and treatment. The term “theranostics” (or “theragnostics”) refers to the combination of diagnosis and therapy of a disease within a single medical procedure or technique. An imaging tracer made with radionuclides is a radioactive tracer. Radionuclide therapy is a form of radiotherapy. A pharmaceutical drug made with radionuclides is called a radiopharmaceutical.
According to the procedure described in the 1975 Aron patent, and the Pharmaceutical Manufacturing Encyclopedia, equimolar amounts of dimethylamine and 2-cyanoguanidine are dissolved in cold toluene to make a concentrated solution, and an equimolar amount of hydrogen chloride is slowly added. The mixture begins to boil, and after cooling, metformin hydrochloride precipitates with a 96% yield. Excess addition of hydrogen chloride results in the formation of the more soluble metformin dichloride salt, a recently reported impurity.
From the 17th century onward, tobacco smoking became virtually central to European social, economic, and cultural history and beyond, entrenching itself in daily rituals, trade networks, and even international conflicts. By the late 17th century, tobacco was used not only for smoking but also as an insecticide. After World War II, over 2,500 tons of nicotine insecticide were used worldwide, but by the 1980s the use of nicotine insecticide had declined below 200 tons. This was due to the availability of other insecticides that are cheaper and less harmful to mammals. The nicotine content of popular American-brand cigarettes has increased over time, and one study found that there was an average increase of 1.78% per year between the years of 1998 and 2005. Although methods of production of synthetic nicotine have existed for decades, it was believed that the cost of making nicotine by laboratory synthesis was cost prohibitive compared to extracting nicotine from tobacco. However, recently synthetic nicotine started to be found in different brands of e-cigarettes and oral pouches and marketed as "tobacco-free".
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.